Chemotherapy for Cranial Base Tumors
Overview
Authors
Affiliations
The tumors I will discuss in this chapter on chemotherapy will be ethesioneuroblastoma, salivary gland tumors, chordoma and nasopharyngeal carcinoma. Due basically to the rarity of these lesions, with the exception of nasopharyngeal carcinoma, there have been no multi-institutional studies of chemotherapy use reported in the literature. As a result, there is no clear-cut consensus on the standard of care as it relates to chemotherapy for these tumors. As with most authors who have previously reviewed these tumor types, I believe it is important for us to propose protocols of therapy and test these in arenas where we can accumulate enough patients for meaningful results. In this way, we can test the apparently active agents and combinations in relapsed or extensive disease. We might also begin to explore concurrent therapy (i.e., concurrent radiation and chemotherapy after the surgical procedure, for example).
Colia V, Provenzano S, Hindi N, Casali P, Stacchiotti S Rep Pract Oncol Radiother. 2016; 21(4):361-9.
PMID: 27330421 PMC: 4899415. DOI: 10.1016/j.rpor.2015.12.005.
Metastatic disease from chordoma.
Vergara G, Belinchon B, Valcarcel F, Veiras M, Zapata I, De La Torre A Clin Transl Oncol. 2008; 10(8):517-21.
PMID: 18667385 DOI: 10.1007/s12094-008-0243-4.
A retrospective clinicopathological study of 37 patients with chordoma: a danish national series.
Safwat A, Nielsen O, Jurik A, Keller J, Weeth E, Lund B Sarcoma. 1997; 1(3-4):161-5.
PMID: 18521219 PMC: 2395368. DOI: 10.1080/13577149778254.
Infantile clivus chordoma without clivus involvement: case report and review of the literature.
Kombogiorgas D, St George E, Chapman S, English M, Solanki G Childs Nerv Syst. 2006; 22(10):1369-74.
PMID: 16565853 DOI: 10.1007/s00381-006-0069-8.
Khairi S, Ewend M Curr Treat Options Neurol. 2002; 4(2):167-173.
PMID: 11827649 DOI: 10.1007/s11940-002-0025-1.